Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

JOURNAL ARTICLE published May 2019 in The Lancet Oncology

Authors: Haruhiro Saito | Tatsuro Fukuhara | Naoki Furuya | Kana Watanabe | Shunichi Sugawara | Shunichiro Iwasawa | Yoshio Tsunezuka | Ou Yamaguchi | Morihito Okada | Kozo Yoshimori | Ichiro Nakachi | Akihiko Gemma | Koichi Azuma | Futoshi Kurimoto | Yukari Tsubata | Yuka Fujita | Hiromi Nagashima | Gyo Asai | Satoshi Watanabe | Masaki Miyazaki | Koichi Hagiwara | Toshihiro Nukiwa | Satoshi Morita | Kunihiko Kobayashi | Makoto Maemondo